As of today (2024-04-26), Gamida Cell's share price is $0.018. Gamida Cell's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-0.02. Hence, Gamida Cell's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Gamida Cell's Price-to-Tangible-Book or its related term are showing as below:
During the past 8 years, Gamida Cell's highest Price to Tangible Book Ratio was 10.04. The lowest was 3.47. And the median was 3.99.
GMDAQ's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.68 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Gamida Cell Price-to-Tangible-Book Historical Data
The historical data trend for Gamida Cell's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gamida Cell's Price-to-Tangible-Book
For the Biotechnology subindustry, Gamida Cell's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gamida Cell's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gamida Cell's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Gamida Cell's Price-to-Tangible-Book falls into.
Gamida Cell Price-to-Tangible-Book Calculation
Gamida Cell's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Gamida Cell Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Gamida Cell's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GMDAQ has been successfully added to your 